Cassava Sciences Inc vs Hewlett Packard Enterprise Co — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Hewlett Packard Enterprise Co trades at $55.95 (market cap $72.01B). The key difference: Hewlett Packard Enterprise Co is far larger — about 1508.1× Cassava Sciences Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | HPE | |
|---|---|---|
Market Cap | $47.75M | $72.01B |
Sector | Health | Technology |
52-Week High | $4.64 | $56.14 |
52-Week Low | $0.87 | $20.01 |
Enterprise Value | -$34.93M | $87.96B |
Dividend Yield | — | 1.05% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
HPE stock trades at $54.67, up 2.72% recently, with a bullish technical signal from moving averages but overbought RSI readings. The company has beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.925. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows. Analysts maintain a consensus buy rating with a $69.81 price target, citing AI infrastructure demand.
The outlook is positive given AI-driven upgrades and institutional buying, but risks include volatile cash flows, elevated debt, and margin pressure. Investors should weigh strong analyst sentiment against execution risks in a competitive market.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →